

Cadila collaborates with Norwegian startup for unique heart treatment

24 January 2019 | News | By Manbeena Chawla

The new drug is based on an invention made by Professor Kjetil Taskén and co-workers at the University of Oslo and Oslo University Hospital.



The Norwegian start-up company SERCA Pharmaceuticals has entered into a unique agreement with the Indian pharmaceutical company Cadila Pharmaceuticals. The agreement is about developing a new and better treatment for patients afflicted with heart attack.

The signing of the agreement took place in New Delhi recently in connection with the official state visit to Prime Minister Erna Solberg.

In the deal, Cadila Pharmaceuticals will use its development organization to make part of the development of a new treatment for patients afflicted with heart attack, which SERCA Pharmaceuticals can advance to global markets.

The new drug is based on an invention made by Professor Kjetil Taskén and co-workers at the University of Oslo and Oslo University Hospital, and SERCA Pharmaceuticals was established by the university's TTO, Inven2.

SERCA Pharmaceuticals will develop a drug treatment for injuries that occur when treating myocardial infarction.